This report covers the market’s current and future potential and examines market drivers and constraints, pipeline medications, the competitive landscape, the regulatory picture, and the epidemiology of neurological disorders. The study segments the market by disease indications, including Parkinson’s, Alzheimer’s, psychotic disorders, epilepsy, autism, multiple sclerosis, and brain tumors, with therapeutic and regional analysis for each. It also profiles smarket participants and competitors across North America, Europe, Asia-Pacific, and the Rest of the World.<\/p>\n
This report is significant at the present time because the global population has grown and aged over the past 30 years, increasing exposure to environmental, metabolic and lifestyle risk factors. Consequently, there has been a notable rise in neurological conditions such as stroke, Alzheimer’s disease, other dementias, and meningitis. Prevalent neurological disorders include cerebrovascular, neurodegenerative, autoimmune, spinal cord issues, intracranial tumors, and craniocerebral trauma. The growing incidence of these conditions, alongside government initiatives and ongoing research, drives market growth in the neurological field.<\/p>\n
The factors driving the market include:<\/b><\/p>\n
Aging Population: <\/b>As people live longer, more individuals are experiencing neurological disorders like dementia and Parkinson’s disease, increasing the demand for treatments.<\/p>\n
Rising Neurological Disorders: <\/b>The global incidence of neurological conditions is growing due to longer life expectancies and better diagnosis, driving the need for improved healthcare services.<\/p>\n
Awareness Initiatives: <\/b>Governments and NGOs are raising awareness about neurological disorders, reducing stigma, and advocating for better prevention and treatment.<\/p>\n
Research and Innovation: <\/b>Ongoing research initiatives are leading to new technologies and treatments in neurology.<\/p>\n
Request a sample copy of <\/b>the global market for neurology report<\/a><\/b>.<\/b><\/p>\n Report Synopsis<\/b><\/p>\n Report Metric<\/b><\/p>\n<\/td>\n Details<\/b><\/p>\n<\/td>\n<\/tr>\n Base year considered<\/p>\n<\/td>\n 2023<\/p>\n<\/td>\n<\/tr>\n Forecast period considered\u00a0\u00a0<\/p>\n<\/td>\n 2024-2029<\/p>\n<\/td>\n<\/tr>\n Base year market size<\/p>\n<\/td>\n $63.0 billion<\/p>\n<\/td>\n<\/tr>\n Market size forecast<\/p>\n<\/td>\n $94.8 billion<\/p>\n<\/td>\n<\/tr>\n Growth rate<\/p>\n<\/td>\n CAGR of 7.1% for the forecast period of 2024-2029<\/p>\n<\/td>\n<\/tr>\n Segments covered<\/p>\n<\/td>\n Disease Indication, Region<\/p>\n<\/td>\n<\/tr>\n Regions covered<\/p>\n<\/td>\n North America, Europe, Asia-Pacific, Rest of the World<\/p>\n<\/td>\n<\/tr>\n Countries covered<\/p>\n<\/td>\n U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Denmark, Belgium, the Netherlands, Sweden, Russia, China, India, Japan, New Zealand, Singapore, Malaysia, Thailand, Indonesia, South Africa, GCC Countries, Brazil, Argentina, Colombia, Paraguay, and Peru<\/p>\n<\/td>\n<\/tr>\n Market drivers<\/p>\n<\/td>\n \u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Growing Geriatric Population with Neurological Disorders<\/p>\n \u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Increasing Global Incidence of Neurological Disorders<\/p>\n \u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Government and NGO Initiatives in Creating Awareness<\/p>\n \u2022\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Research Initiatives in Neurology<\/p>\n<\/td>\n<\/tr>\n Interesting facts:<\/b><\/p>\n Emerging startups:<\/b><\/p>\n The report addresses the following questions:<\/b><\/p>\n Market leaders include:<\/b><\/p>\n Related Reports:<\/b><\/p>\n Alzheimer’s Disease Therapeutics and Diagnostics: Global Markets<\/a><\/b>: <\/b>This report focuses on biomarker tests for AD in the diagnostics segment, excluding cognitive tests and neuroimaging methods. The therapeutics segment covers only pharmacological treatments, excluding alternative treatments and off-label drug use. The market is segmented by test type, region, purpose, drug class, drug type, and disease stage. The report discusses clinical trials, innovations, opportunities, and the latest AD diagnostics and therapeutics trends.<\/p>\n Breakthrough Therapies: Market Dynamics and Investment Opportunities<\/a><\/b>: <\/b>This report explores the potential risks and benefits of breakthrough therapy designation (BTD), comparing fast-track drug development approaches and highlighting the opportunities and challenges in creating breakthrough therapies. It covers therapy areas for cardiovascular, neurology, rare diseases, and oncology, and analyzes leading companies, their products and their revenues.\u00a0<\/p>\n Navigate Uncertainty with Confidence<\/b><\/p>\n In times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we’re here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape\u2014giving you the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That’s why, for a limited time, we’re offering 30% off\u00a0the price of any BCC Research report to help more organizations gain access to our latest data and insights.<\/p>\n Purchase a <\/b>copy of the report<\/a><\/b>\u00a0direct from BCC Research.<\/b><\/p>\n For further information or any of these reports or to make a purchase, contact info@bccresearch.com<\/a>.\u00a0\u00a0\u00a0\u00a0<\/p>\n About BCC Research<\/b><\/p>\n BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts’ goal is to help you make informed business decisions free of noise and hype.<\/p>\n Contact Us<\/b><\/p>\n Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA<\/p>\n Email: info@bccresearch.com<\/a><\/p>\n Phone: +1 781-489-7301<\/p>\n For media inquiries, email press@bccresearch.com<\/a> or visit our media page<\/a> for access to our market research library.<\/p>\n Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC<\/a> as the source and publisher.<\/p>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n
\n
<\/b>The global neurology market was valued at $63.0 billion in 2023 and is expected to reach $94.8 billion by the end of 2029, at a\u00a0CAGR of 7.1% from 2024 to 2029.<\/li>\n
<\/b>Government and NGO initiatives designed to increase awareness of the increasing global incidence of neurological disorders, the growing geriatric population with neurological disorders, and research initiatives in neurology.<\/li>\n
<\/b>The global neurology market is segmented based on disease indication and region.<\/li>\n
<\/b>The multiple sclerosis segment will dominate the market\u00a0for the next four years.<\/li>\n
<\/b>North America holds the largest share of the market.<\/li>\n<\/ol>\n\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=EN93615&Transmission_Id=202505211425PR_NEWS_EURO_ND__EN93615&DateId=20250521\")
<\/p>\n","protected":false},"excerpt":{"rendered":"“Increased Prevalence of Chronic Neurological Conditions and Enhanced Healthcare Infrastructure Drive Neurology Market Growth in Unexplored Markets” BOSTON,…\n","protected":false},"author":2,"featured_media":120515,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[23880,51,2441,16,15],"class_list":{"0":"post-120514","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-bcc-research-llc","9":"tag-business","10":"tag-markets","11":"tag-uk","12":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114547332476887171","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/120514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=120514"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/120514\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/120515"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=120514"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=120514"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=120514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}